A 3D bioengineered human liver for the study of acute and chronic drug-induced hepatotoxicity and fibrosis
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index; 16 of the 31 sources its claims cite were checked for support.
Abstract
The liver is frequently exposed to acute and chronic insults that disrupt its function, leading to inflammation, fibrosis, and serious conditions like cirrhosis and hepatocellular carcinoma. Fibrosis, driven by the activation of hepatic stellate cells is a key feature of chronic liver damage. Traditional 2D liver models face limitations in maintaining liver functions and accurately replicating chronic conditions like fibrosis. In response to these needs, 3D models have emerged as more physiologically relevant platforms for studying liver disease and drug testing. However, most existing 3D models still lack chronic injury features or immune elements. In this study, we developed a 3D human-liver model to investigate both acute and chronic drug-induced liver injury. The model consists of encapsulated human hepatocytes (HepaRG) and hepatic stellate cells (LX-2) within a gelatin methacryloyl (GelMA) and carboxymethyl cellulose methacrylate matrix. Over a 30-day culture period, the 3D liver constructs maintained physiologically relevant functions, including albumin secretion and cytochrome P450 activity, which are lost rapidly in conventional 2D models. The model enabled reliable simulation of low-level, long-term, and high-dose, short-term damage by administering lipopolysaccharide and Paracetamol. Chronic liver injury was characterized by progressive fibrosis, elevated expression of COL1A1, and persistent hyperammonemia. In contrast, acute models showed significant but transient injury. Moreover, dexamethasone treatment successfully reversed fibrotic markers and restored hepatocyte functionality, indicating the model's predictive power for evaluating potential therapies. Incorporating human monocytes (THP-1) allowed investigation of the immune response and macrophage activation, which are critical contributors to liver disease pathogenesis. Overall, this 3D liver model offers a physiologically relevant and versatile platform for studying complex multi-cellular interactions under acute and chronic injury. It has broad implications for drug safety screening, disease modeling, and personalized therapy. The tri-culture design extends the model's capacity to elucidate immune-driven hepatic pathology.
Overview
CoChat Summary
TL;DR
This paper develops a 3D human liver tissue model (HepaRG hepatocytes + LX-2 stellate cells, later with THP-1 monocytes) that stays functional for 30 days and reproduces both chronic and acute drug-induced liver injury. It shows progressive fibrosis, metabolic dysfunction, and inflammatory activation under LPS + paracetamol challenge, and dexamethasone reverses many of these injury markers.
Key findings
- The 3D liver constructs maintained viability and liver function for up to 30 days: MTS and Live/Dead assays showed no significant viability decline, CYP3A4 activity increased at days 10, 20, and 30 vs day 0 (p < 0.0001), and albumin, CPS1, and OTC expression increased over time.
- Under chronic injury conditions (LPS 10 ng/mL + paracetamol 0.75 mM), the model showed progressive fibrosis and impaired function: COL1A1 increased over days 10–30, PIIINP and PINP were higher from day 10 to day 30 (p < 0.01), IL-6 and MCP-1 increased, and chronic-damage samples had 528 downregulated genes in the Untreated Day 0 vs Chronic Day 30 comparison.
- Chronic damage also reduced metabolic capacity: CYP3A4 activity was significantly lower at all time points, live/dead assays showed an approximately 50% decline in cell viability starting at day 10, and nuclear area increased significantly from day 10 onward (p < 0.0001).
- Acute injury (LPS 100 ng/mL + paracetamol 2.5 mM) caused rapid dysfunction by day 3: Live/Dead and MTS both dropped significantly, CYP3A4 activity fell (p < 0.0001), albumin and CPS1 mRNA decreased, COL1A1 increased (p < 0.05), and ammonia levels rose (p < 0.01).
Methods
- Human 3D liver tissues were fabricated by encapsulating HepaRG hepatocytes and LX-2 hepatic stellate cells in a GelMA-CMCMA hydrogel using PDMS ring molds; the standard ratio was 2:1 (HepaRG:LX-2), with cultures maintained in serum-free differentiation medium for up to 30 days.
- Chronic injury was induced with LPS 10 ng/mL + paracetamol 0.75 mM for 30 days; acute injury with LPS 100 ng/mL + paracetamol 2.5 mM for 3 days; dexamethasone 100 nM was used to test rescue in both models.
- Analyses included Live/Dead staining, MTS assay, CYP3A4 activity assay, immunofluorescence/confocal imaging, qPCR, RNA-seq with DESeq2 and GSEA, ammonia/PINP/PIIINP measurements, and transwell co-culture with THP-1 monocytes plus NF-κB luciferase and cytokine assays.
Limitations
- The paper states that the model does not fully represent other non-parenchymal liver cells, such as endothelial cells and Kupffer cells, which may limit how completely it captures liver pathophysiology.
- It also states that patient-specific genetic and etiological factors are not accounted for because standardized cell lines are used.
- Evident from the text: the model relies on transformed/immortalized cell lines and transwell co-culture rather than fully primary human liver tissue, which may constrain translational generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
9 Valid · 4 Not valid · 8 Not checked · 185 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“The inclusion of hepatic stellate cells (HSCs) in the 3D GelMA matrix prevented their spontaneous activation, a frequent complication when HSCs are cultured on rigid 2D substrates (Brovold, 2021; Brovold, 2020).”
§ A 3D bioengineered human liver for the study of acute and chronic drug-induced hepatotoxicity and fibrosis > Discussion
What the sources say
- Disputedcites Brovold, 2021 sourceExperimental — accuracy not yet measured
The Results describe HSCs encapsulated in a collagen I hydrogel, not a GelMA matrix. The Discussion says both HSC types in the organoids were activated based on α-SMA expression, contrary to the claim that 3D inclusion prevented activation. It does support the narrower point that culture on plastic dishes can activate HSCs. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
- Partly supportedcites Brovold, 2020 sourceExperimental — accuracy not yet measured
The Methods (page unavailable in our copy) say the HSCs were passaged on standard culture plates to ensure activation, supporting the point that 2D culture can activate them. But the study encapsulated already-activated HSCs in a 3D collagen I gel, not GelMA, and does not report that encapsulation prevented spontaneous activation. (LLM, conf=0.89)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Macrophage and monocyte recruitment is vital in the pathogenesis of liver disease, as these cells secrete inflammatory mediators that aggravate hepatocyte injury and promote further HSC activation (Gröger M, 2016).”
§ A 3D bioengineered human liver for the study of acute and chronic drug-induced hepatotoxicity and fibrosis > Discussion
What the sources say
- Disputedcites Gröger M, 2016 sourceExperimental — accuracy not yet measured
The Discussion reports that recruited monocytes increased pro-inflammatory cytokine release, but appeared to dampen inflammation-induced hepatocellular dysfunction. The Results likewise report reduced cell-damage markers after monocyte invasion—the opposite of the claimed aggravation of hepatocyte injury. The paper describes HSCs secreting chemoattractants for macrophages, not recruited monocytes promoting HSC activation. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“One of the principal achievements of this work is the model’s capacity to support extended cell viability and phenotypic maintenance for up to 30 days, as indicated by sustained albumin expression, stable cytochrome P450 (CYP450) activity, and effective ammonia detoxification pathways in untreated samples (Zurlo J, 1996; Bachour-El Azzi, 2022; Huch M, 2015) (Figures 1C,D,G).”
§ A 3D bioengineered human liver for the study of acute and chronic drug-induced hepatotoxicity and fibrosis > Discussion
What the sources say
- Not checked — no full text of the sourcecites Zurlo J, 1996 source
- Not checked — no full text of the sourcecites Bachour-El Azzi, 2022 source
- Partly supportedcites Huch M, 2015 sourceExperimental — accuracy not yet measured
The Results section, “Differentiation into Functional Hepatocytes In Vitro and upon Transplantation” (page unavailable), reports albumin secretion, CYP3A4 activity, and ammonia detoxification in differentiated liver organoids. It does not establish that these functions remained stable for 30 days in untreated samples. The Experimental Procedures, “Data Analysis” (page unavailable), describe ammonia testing after approximately 11 days of differentiation, not a 30-day assessment. (LLM, conf=0.88)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“While several cellular models have been established to investigate acute hepatotoxicity, evaluating chronic liver damage has traditionally relied on animal models (Smith, 2024; Ma, 2009).”
§ A 3D bioengineered human liver for the study of acute and chronic drug-induced hepatotoxicity and fibrosis > Discussion
What the sources say
- Partly supportedcites Smith, 2024 sourceExperimental — accuracy not yet measured
The Methods section (‘Chronic and acute liver injury mouse models’; page not provided) describes using NSG-PiZ mice to model chronic liver injury, and the Introduction describes prior preclinical mouse models. The paper therefore supports the use of animal models, but it does not establish that evaluation of chronic liver damage has traditionally relied on them rather than cellular models. (LLM, conf=0.84)
- Not matchedcites Ma, 2009
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“COL1A1 mRNA levels progressively increased in the chronic damage model through Days 10, 20, and 30 (p < 0.0001 at day 20), reflecting ongoing HSC activation and extracellular matrix deposition.”
§ A 3D bioengineered human liver for the study of acute and chronic drug-induced hepatotoxicity and fibrosis > Functional assays: CYP3A4 activity and fibrosis markers
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
116 more claims
Create a free account to see all 206 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 75
- The quote only partly states this claim. 1
- Probably not a substantial claim. 10
Citations
Cites
Long-Term Culture of Genome-Stable Bipotent Stem Cells from Adult Human Liver
Huch, M., Gehart, H., van Boxtel, R., Hamer, K., Blokzijl, F., Verstegen, M. M. A., Ellis, E., van Wenum, M., Fuchs, S. A., de Ligt, J., et al. (2015) · Cell · doi:10.1016/j.cell.2014.11.050 · Cited by 1,619
Bell, C. C., Hendriks, D. F. G., Moro, S. M. L., Ellis, E., Walsh, J., Renblom, A., Fredriksson Puigvert, L., Dankers, A. C. A., Jacobs, F., Snoeys, J., et al. (2016) · Scientific Reports · doi:10.1038/srep25187 · Cited by 739
Taru, V., Szabo, G., Mehal, W., & Reiberger, T. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.06.016 · Cited by 344 · cited 1×
“In contrast, chronic liver disease (CLD) arises from sustained injury and inflammation, eventually leading to fibrosis and cirrhosis (Taru V, 2024).”
Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury
Proctor, W. R., Foster, A. J., Vogt, J., Summers, C., Middleton, B., Pilling, M. A., Shienson, D., Kijanska, M., Ströbel, S., Kelm, J. M., et al. (2017) · Archives of Toxicology · doi:10.1007/s00204-017-2002-1 · Cited by 328 · cited 1×
“Proctor et al. (Proctor et al., 2017) showed that liver microtissues combining hepatocytes with HSCs, Kupffer, and endothelial cells outperformed 2D systems (87% sensitivity, 92% specificity) and better reflected clinical DILI data.”
Akkız, H., Gieseler, R. K., & Canbay, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147873 · Cited by 191
Composite Biomaterials as Long‐Lasting Scaffolds for 3D Bioprinting of Highly Aligned Muscle Tissue
García‐Lizarribar, A., Fernández‐Garibay, X., Velasco‐Mallorquí, F., Castaño, A. G., Samitier, J., & Ramón‐Azcón, J. (2018) · Macromolecular Bioscience · doi:10.1002/mabi.201800167 · Cited by 154
Self-citationWang, R., Li, Z., Liu, S., & Zhang, D. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1061453 · Cited by 140
A critical perspective on 3D liver models for drug metabolism and toxicology studies
Serras, A. S., Rodrigues, J. S., Cipriano, M., Rodrigues, A. V., Oliveira, N. G., & Miranda, J. P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.626805 · Cited by 138
Acute liver failure: mechanisms of hepatocyte injury and regeneration
Rutherford, A., & Chung, R. (2008) · Seminars in Liver Disease · doi:10.1055/s-2008-1073116 · Cited by 131 · cited 1×
“…later decrease likely marks exhaustion of this reserve and progression toward chronic hepatocyte dysfunction, mirroring hallmarks of advanced liver injury such as impaired urea cycle function and reduced albumin synthesis (Barle et al., 2006; Amouzandeh et al., 2023; Rutherford and Chung, 2008).”
The types of hepatic myofibroblasts contributing to liver fibrosis of different etiologies
Xu, J., Liu, X., Koyama, Y., Wang, P., Lan, T., Kim, I.-G., Kim, I. H., Ma, H.-Y., & Kisseleva, T. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00167 · Cited by 126 · cited 1×
“Following damage, monocytes are recruited to the liver, differentiating into macrophages that secrete pro-inflammatory cytokines and chemokines (e.g., TNF-alpha, IL-1beta, TGF-beta) (Xu J, 2014).”
Influential
Metadata
- Authors
- Ferret-Miñana, A., Alcaraz, E., Horrillo, R., Ramón-Azcón, J., & De Chiara, F.
- Affiliations
- Institute for Bioengineering of Catalonia (ES)
- Grifols (Germany) (DE)
- Biosensors for Bioengineering Group, Institute for Bioengineering of Catalonia (IBEC)
- Venue
- Frontiers in Bioengineering and Biotechnology
- Publisher
- Frontiers Media SA
- Published
- 2026-05-11
- Volume
- 14
- Pages
- 1798323-1798323
- ISSN
- 2296-4185 (ISSN-L)
- PMC
- PMC13198925
- OpenAlex
- W7160761852
- Cited by
- 0
- References
- 32
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Bioengineering and Biotechnology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Grifols
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
- Keywords
- 3D liver model, drug-induced liver injury, liver fibrosis, hepatic stellate cells, gelatin methacryloyl, lipopolysaccharide, paracetamol, dexamethasone, hyperammonemia, COL1A1, THP-1 cells, macrophage activation, drug safety testing, hepatocyte function
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A 3D bioengineered human liver for the study of acute and chronic drug-induced hepatotoxicity and fibrosis. https://app.cochat.ai/papers/10.3389/fbioe.2026.1798323
- The paper
- Ferret-Miñana, A., Alcaraz, E., Horrillo, R., Ramón-Azcón, J., & De Chiara, F. (2026). A 3D bioengineered human liver for the study of acute and chronic drug-induced hepatotoxicity and fibrosis. Frontiers in Bioengineering and Biotechnology. https://doi.org/10.3389/fbioe.2026.1798323
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.